Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Drug Administration (FDA) has ac ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. related to alleged fiduciary breaches concerning the Phase 3 EFZO-FIT clinical trial disclosures [1][2] Investigation Background - The investigation covers the period from November 7, 2024, to September 12, 2025, focusing on allegations that aTyr and certain executives made false and/or misleading statements regarding the Phase 3 trial results [2][3] - Following the negative results from the Phase 3 trial, aTyr's stock price experienced a significant decline [2] Board Oversight - The investigation is examining whether aTyr's board failed to adequately oversee clinical disclosure controls and allowed overly optimistic representations that could expose the company to litigation and reputational risks [3] Shareholder Guidance - Current aTyr shareholders who held their shares continuously before November 7, 2024, may have the standing to pursue derivative claims on behalf of the company [2]

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr†or the "Company†) (NASDAQ: ATYR) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements After aTyr Pharma ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs’ rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against aTyr Pharma, Inc. (NASDAQ: ATYR). The litigation follows a catastrophic 83% single-day stock collapse after the company’s flagship drug trial failed to meet its primary endpoint. The lawsuit alleges that aTyr and its executives provided materially false and ...

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant stock price decline after the failure of a key clinical study [1][2]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly regarding the drug's ability to allow patients to taper off steroids completely [1]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48 [1]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of aTyr during the specified class period are encouraged to register for the class action, with a deadline set for December 8, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1]. - There is a deadline of December 8, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [4]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [5]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [5]. Group 3: Market Impact - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025 [1]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Background - The complaint alleges that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5]. - The lawsuit claims that when the true information became public, investors suffered damages due to the misleading nature of the statements made by the company [5].

Core Viewpoint - A securities class action lawsuit has been filed against aTyr Pharma, Inc. following an 83% drop in stock price after the failure of its drug trial for Efzofitimod, which did not meet its primary endpoint [1][2][3]. Summary by Relevant Sections Allegations - The lawsuit claims that aTyr and its executives provided materially false and misleading information regarding the efficacy of Efzofitimod, leading to inflated stock prices [2][3]. - The firm alleges that aTyr concealed critical adverse facts about the drug's ability to allow patients to taper off steroids, which is a key measure of its efficacy [3][4]. Legal Focus - The primary legal focus is whether aTyr misrepresented the drug's true ability to help patients reduce steroid dependency, particularly in light of the failed primary endpoint in the Phase 3 EFZO-FIT study [5]. - The investigation is centered on the discrepancy between the company's optimistic public statements and the actual performance of the drug in clinical trials [4][5]. Market Impact - Following the announcement of the trial failure, aTyr's stock plummeted from $6.03 to $1.02, representing an 83.2% loss on September 15, 2025 [5]. - The lawsuit seeks to determine if investors are entitled to damages due to the alleged wrongful acts and omissions by the company [5]. Next Steps for Investors - Investors who purchased aTyr shares during the class period (November 7, 2024, through September 12, 2025) and experienced significant losses are encouraged to submit their claims by the December 8, 2025 deadline [6].

Group 1 - The article highlights the upcoming deadline of December 8, 2025, for investors to participate as lead plaintiffs in a securities fraud class action lawsuit against aTyr Pharma Inc. [1] - The lawsuit is on behalf of investors who acquired aTyr Pharma Inc. common stock during the class period from November 7, 2024, to September 12, 2025 [1] - The notice serves as a reminder for investors who lost money on aTyr Pharma Inc. to take action [1]

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant stock price decline after the failure of a key study [1][2]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements while concealing material adverse facts about Efzofitimod's ability to allow patients to taper steroid usage [1]. - The EFZO-FIT study did not meet its primary endpoint, which was announced on September 15, 2025, leading to a drastic stock price drop from $6.03 to $1.02, a decline of 83.2% in one day [1]. - The company plans to engage with the FDA to determine the next steps following the disappointing study results [1]. Group 2: Class Action Details - Shareholders who purchased shares during the class period from November 7, 2024, to September 12, 2025, are encouraged to register for the class action, with a deadline of December 8, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].